Research programme: PARP inhibitors - Inotek

Drug Profile

Research programme: PARP inhibitors - Inotek

Latest Information Update: 24 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Age-related macular degeneration; Asthma; Chronic obstructive pulmonary disease; Diabetes mellitus; Diabetic retinopathy; Erectile dysfunction; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Stroke

Most Recent Events

  • 11 Jan 2011 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
  • 11 Jan 2011 Preclinical trials in Diabetic retinopathy in USA (unspecified route)
  • 13 Sep 2007 Discontinued - Preclinical for Acute lung injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top